

Oprozomib

Catalog No: tcsc2767



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

935888-69-0

Formula:

$C_{25}H_{32}N_4O_7S$

Pathway:

Metabolic Enzyme/Protease;Autophagy

Target:

Proteasome;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 50 mg/mL (93.88 mM)

Alternative Names:

ONX 0912;PR-047

Observed Molecular Weight:

532.61


Product Description

Oprozomib (ONX 0912; PR047) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β 5/LMP7 with IC₅₀ of 36 nM/82 nM.

IC₅₀ value: 36 nM/82 nM(20S proteasome β 5/LMP7) [1]

Target: 20S proteasome

The anti-MM activity of Oprozomib is associated with activation of caspase-8, caspase-9, caspase-3, and PARP, as well as inhibition of migration of MM cells and angiogenesis. Oprozomib is demonstrated an absolute bioavailability of up to 39% in rodents and dogs. It is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response in multiple human tumor xenograft and mouse syngeneic models.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!